News

Filter

Current filters:

ImnovidBiotechnology

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

15-10-2014

UK medical costs watchdog the National Institute for Health and Care Excellence (NICE) has issued preliminary…

BiotechnologyCelgene Corp.ImnovidOncologyPricingRegulationUK

Celgene’s Imnovid now reimbursed in Sweden, Spain and Switzerland

Celgene’s Imnovid now reimbursed in Sweden, Spain and Switzerland

11-07-2014

US biotech firm Celgene’s Imnovid (pomalidomide), called Pomalyst in the USA, is now approved for reimbursement…

BiotechnologyCelgeneFinancialHealthcareImnovidOncologyPomalystSpainSweden

Celgene's pomalidomide meets primary endpoint in multiple myeloma

05-09-2013

US biotech major Celgene (Nasdaq: CELG) announced that positive updated results from MM-003, a Phase…

BiotechnologyCelgeneImnovidOncologypomalidomidePomalystResearch

Pomalidomide Celgene OKed in Europe

09-08-2013

The European Commission has granted approval for US biotech firm Celgene's (Nasdaq: CELG) Pomalidomide…

BiotechnologyCelgeneEuropeImnovidOncologypomalidomidePomalidomide CelgeneRegulation

COMPANY SPOTLIGHT

Menarini

Back to top